Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma. - sprookjes - yvandenbroek - TriplyDB

Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.

Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.

http://www.wikidata.org/entity/Q35062108

about

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.Short androgen receptor poly-glutamine-promoted endometrial cancer is associated with benzo[a]pyrene-mediated aryl hydrocarbon receptor activation.Estrogen, Estrogen Receptor and Lung Cancer [Recent Advances in Association of Estrogen and Non-small Cell Lung Cancer].[Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells].

P2860

Q35808124-D6458901-9463-4D08-A1CE-F514857DE338 Q37564767-24729BEC-2E35-4C8C-857C-80F7931C5B49 Q39004424-6B4A6480-6267-4855-9CF7-752406DFE04F Q40092714-C9B64E25-ABEF-498E-8FE5-861628B09AD5 Q41573792-2A57D1C2-17F4-4AC3-B982-2344002E4C5E Q53731672-3C89AB4E-B6A7-4E62-8895-3248407A3A77 Q55513856-C39E59D2-4A38-480D-9625-A94A74A5DA05

P2860

Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.

http://www.wikidata.org/entity/Q35062108

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@ast

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@en

type

label

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@ast

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@en

prefLabel

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@ast

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@en

P1433

Q35062108-C5461B6B-E49D-4C46-9CF5-F58100E419B2

P1476

Q35062108-94104570-3386-4C86-A86B-7C27749F3866

P2093

Q35062108-030084C8-59C6-4F18-A72E-43626ACA1F40

Q35062108-24373891-74B1-4F92-8875-99E3A8D398CD

Q35062108-37B8E5D3-4642-45E2-ABDA-DB7ED2AA3A45

Q35062108-57347CD1-4B93-4A4A-A4C8-63AA93212F4F

Q35062108-8CAAB43D-C8AC-41C8-BBF6-780C788E958E

Q35062108-F2AEBBA3-3CBB-44CD-849D-01225E0C3C6F

P2860

Q35062108-07BC60E6-3F25-40C7-962C-B7E9493EAD69

Q35062108-0FB850E4-60D3-47FE-9C60-03962DD3A04C

Q35062108-14A8D137-AE9E-4D93-ACEC-4E611869AD9C

Q35062108-1D6D26DD-4C32-49A4-98CF-BDE9F10069C0

Q35062108-28489BE2-B7C5-445C-9EFD-EAA1162C4739

Q35062108-2980D8C7-E7FD-49B8-9E42-D208D9F53541

Q35062108-3218AEA1-B3F9-49FD-BFBE-C55A406040EA

Q35062108-36DF9E64-42C8-4499-8026-F929432D3BA2

Q35062108-38663EC6-2C78-47BB-BD03-74B27CFE86B9

Q35062108-38E130E5-C712-4F2D-899C-FC7AADB88981

P304

Q35062108-5FE0E402-792C-415B-B155-8444526F93E3

P31

Q35062108-D3FB5C4E-D4FA-46E4-B3BA-84387067F281

P356

Q35062108-B9AA9E12-9417-4800-97EB-BBD9EB75FBE2

P407

Q35062108-43780B68-A768-4220-84F5-ACDC6D26A51E

P478

Q35062108-B05BD22D-4DB3-4CCC-9F45-1F55F7947D51

P50

Q35062108-3B87757C-977A-4ECA-958C-32793033492A

Q35062108-996DAE41-373A-48F0-AC75-A7F017772201

Q35062108-A24911CD-0AB7-4C88-B339-0C43EA0EA27A

Q35062108-BA1A9AE8-0FB0-4D69-A8A9-D759E44414EC

P577

Q35062108-C0F625E5-568D-40A3-985A-CF1788E13D52

P5875

Q35062108-653F19F8-6473-46B9-ADB1-C902C27956B7

P698

Q35062108-613781BB-AF7B-44F9-919E-0EBD66B523DE

P932

Q35062108-977E66C6-675E-49A1-83A5-749C8F7EAD08

P356

P1433

BioMed Research International

P1476

Potential therapeutic benefit ...... advanced lung adenocarcinoma.

@en

P2093

Kuo-Liang Chiu

http://www.w3.org/2001/XMLSchema#string

Li-Hsiou Chen

http://www.w3.org/2001/XMLSchema#string

Shang-Miao Chang

http://www.w3.org/2001/XMLSchema#string

Shu-Yun Yang

http://www.w3.org/2001/XMLSchema#string

Tzu-Sheng Chen

http://www.w3.org/2001/XMLSchema#string

Yung-Lun Ni

http://www.w3.org/2001/XMLSchema#string

P2860

An inherent role of microtubule network in the action of nuclear receptor

Cancer treatment and survivorship statistics, 2012

Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Estrogen signaling in lung cancer: an opportunity for novel therapy

Estrogen receptor signaling in lung cancer

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

Screening for epidermal growth factor receptor mutations in lung cancer

Identification and characterization of estrogen receptor variants in prostate cancer cell lines.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

P304

642041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2015/642041

http://www.w3.org/2001/XMLSchema#string

P407

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272170750

http://www.w3.org/2001/XMLSchema#string

P698

25692143

http://www.w3.org/2001/XMLSchema#string

P932

4321093

http://www.w3.org/2001/XMLSchema#string